Join to view full profile
333 Cottman AvePhiladelphia, PA 19111
Phone+1 215-728-2500
Fax+1 215-728-3639
Dr. Lubiniecki is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2001
Johns Hopkins University School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2001 - 2026
NJ State Medical License 2004 - 2009
MN State Medical License 1999 - 2001
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Publications & Presentations
PubMed
- 51 citationsLenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.Robert J Motzer, Matthew H Taylor, Thomas R Jeffry Evans, Takuji Okusaka, Hilary Glen
Expert Review of Anticancer Therapy. 2022-04-01 - 57 citationsThe LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.Matthew H. Taylor, Emmett V. Schmidt, Corina E. Dutcus, Elaine M. Pinheiro, Yasuhiro Funahashi
Future Oncology. 2021-02-01 - 215 citationsLong-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 S...Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Jose Luis Perez-Gracia
Journal of Clinical Oncology. 2020-02-20
Press Mentions
Rainbows, Pickleball and Puppies: Inside the ‘Enduring Activism’ and ‘Cautious Optimism’ at ASH 2025December 9th, 2025- ASH: Merck Mulls Future of Polycythemia Program While Takeda Takes Phase 3 Victory LapDecember 8th, 2025
- Merck Begins Trial Evaluating Zilovertamab Vedotin for Previously Untreated Diffuse Large B-cell LymphomaFebruary 8th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
